NYSE$USPH

US Physical Therapy Inc · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Briefing

US Physical Therapy Q4 2025 Earnings Report

US Physical Therapy delivered a strong finish to 2025 with record patient volumes and significant margin improvement. The company saw its seventh consecutive quarter of record visits per clinic per day and successfully managed costs despite inflationary pressures, while announcing major long-term hospital affiliation agreements expected to drive substantial growth in 2027.

  • Achieved record average visits per clinic per day of 32.7 in Q4, the highest in company history.
  • Physical therapy adjusted gross margin increased approximately 200 basis points to 20.5% in Q4.
  • Announced two significant hospital arrangements expected to contribute at least $14 million in EBITDA by 2027.
  • Total patient visits increased 11.2% year-over-year, driven by organic growth and acquisitions.

Headline financials

Total Revenue

$200M

Previous: $180M+10.8%
EPS (adj)

$0.67

Previous: $0.51+31.4%
Visits per Clinic per Day

32.7

Previous: 32.2+1.6%
Total Patient Visits

1.6M

Previous: 1.4M+11.2%
Net Rate per Visit

$106.49

Previous: $104.73+1.7%
Home Care Visits

32.7K

No prior period
Net Income

$10.2M

Previous: $9.24M+10.3%
Operating Income

$10.2M

Previous: $14.5M-29.8%
Cash & Equivalents

$35.6M

Previous: $41.4M-13.9%

Revenue & EPS history

US Physical Therapy · Revenue · Quarterly

$200M

Q4 2025+10.8%vs Q4 2024
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Revenue by segment

US Physical Therapy · $203M total across 2 segments · Q4 2025

  • Physical Therapy Operations
    $174M+13.0%
  • Injury Prevention
    $28.7M+8.7%

Forward guidance

Full year 2026 adjusted EBITDA is expected to be between $102 million and $106 million.

Tailwinds

  • Incremental $2.5 million revenue from Medicare rate increase.
  • Implementation of ambient listening documentation AI for efficiency.
  • Expected $14 million EBITDA lift from new hospital affiliations by 2027.
  • Semi-virtualization of front desk and intake operations to lower costs.
  • Return to pressing forward with remote therapeutic monitoring (RTM).

Headwinds

  • Hospital affiliations will only begin to phase-in mid-year 2026.
  • Continued inflationary environment impacting operating costs.
  • IIP margins can be dilutive when signing very large new contracts.
  • Implementation costs of $600k for new enterprise-wide financial system.
  • Medicare Advantage rates not all tied to the favorable CMS schedule.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-0.6%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-1.5%

Avg return

30 days after

53%

35 / 66 earnings

Positive

+17.3%

Q3 2024

Best reaction

-27.5%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.5%+1.3%
Q4 2025-2.9%+1.9%-8.5%
Q3 2025+0.9%-15.8%-13.8%
Q2 2025+14.7%+20.4%+17.8%
Q1 2025-0.1%+8.8%+8.9%
Q4 2024-6.0%-9.5%-18.0%
Q3 2024+17.3%+14.8%+17.9%
Q2 2024-6.8%-3.9%-5.4%
Q1 2024-2.2%+0.2%-8.0%
Q4 2023+3.4%+2.8%+9.8%
Q3 2023-2.8%-3.3%+4.3%
Q2 2023-8.6%-8.1%-19.8%
Q1 2023+4.5%+10.1%+2.1%
Q4 2022+2.1%+2.2%-5.7%
Q3 2022-8.9%-4.0%-0.3%
Q2 2022-27.5%-29.9%-37.0%
Q1 2022-4.4%-4.1%+4.2%
Q4 2021-5.8%-6.5%-2.1%
Q3 2021-3.6%-8.2%-21.6%
Q2 2021-3.6%-5.4%-1.1%
Q1 2021+6.0%+4.5%+6.6%
Q4 2020-17.2%-19.8%-24.3%
Q3 2020+8.4%+26.6%+29.2%
Q2 2020+2.4%+1.1%+3.7%
Q1 2020-1.0%+2.7%+0.9%
Q4 2019-17.7%-16.0%-49.0%
Q3 2019-20.1%-20.4%-20.5%
Q2 2019+3.9%+6.1%+8.1%
Q1 2019+2.3%+3.3%-1.2%
Q4 2018+3.2%+3.4%+2.1%
Q3 2018+5.1%+6.5%+10.7%
Q2 2018+8.9%+7.0%+18.9%
Q1 2018-1.4%-0.5%+2.4%
Q4 2017+6.8%+2.7%+4.9%
Q3 2017-2.6%-2.9%+5.7%
Q2 2017+2.4%+2.6%-2.9%
Q1 2017-6.0%+0.8%-2.1%
Q4 2016+1.7%+2.0%-1.2%
Q3 2016-1.2%+0.5%+14.3%
Q2 2016+4.7%+4.0%+9.7%
Q1 2016+12.7%
Q4 2015+1.2%
Q3 2015+2.3%
Q2 2015-5.0%
Q1 2015+7.9%
Q4 2014+5.4%
Q3 2014-7.2%
Q2 2014+5.8%
Q1 2014+3.0%
Q4 2013-0.3%
Q3 2013-7.1%
Q2 2013+6.0%
Q1 2013+3.5%
Q4 2012-4.6%
Q3 2012+0.6%
Q2 2012+0.6%
Q1 2011+1.0%
Q1 2012+2.1%
Q4 2009-0.2%
Q4 2011-0.2%
Q3 2010+1.9%
Q3 2011+1.9%
Q2 2011-10.9%
Q4 2010-10.9%
Q2 2010-10.9%
Q1 2010+12.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro